Technology
Health
Biotechnology

Bio-Path Holdings

$21.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.70 (-14.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BPTH and other stocks, options, ETFs, and crypto commission-free!

About

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. Read More The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.

Employees
9
Headquarters
Bellaire, Texas
Founded
2007
Market Cap
16.77M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
939.37K
High Today
$24.75
Low Today
$21.30
Open Price
$24.75
Volume
557.30K
52 Week High
$73.52
52 Week Low
$1.61

Collections

Technology
Health
Biotechnology
Medical
US
North America

News

Seeking Alpha11h

Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q 2018 Results - Earnings Call Transcript

Bio-Path Holdings (NASDAQ:BPTH) Q4 2018 Earnings Conference Call March 20, 2019 8:30 AM ET Company Participants Peter Nielsen - President, Chief Executive Officer Anthony Price - Vice President, Finance and Accounting Will O’Connor - Stern Investor Relations Conference Call Participants Laura Engle - Stonegate Capital Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings full year 2018 earnings conference call. At this time, all participants are in a listen-only mode. Followin...

963
Associated Press12h

Bio-Path Holdings Reports Full Year 2018 Financial Results

HOUSTON, March 20, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2018 and provided an update on recent corporate developments. “Throughout 2018, we made great progress in pursuit of our mission of bringing innovative new RNAi nanoparticle therapeutics to...

443
MarketWatchMar 19

AbbVie Inc. Stock Quote (U.S.: NYSE)

Shares of Bio-Path Holdings Inc. shot up another 130% on Thursday morning, one day after the company announced an update to its Phase 2 trial data on prexigebersen, a potential therapy for patients with acute myeloid leukemia (AML). The tiny biotech was the most heavily traded stock on the Nasdaq on Wednesday afternoon, with shares rocketing 160%. The trial enrolled 17 patients and looked at the safety and efficacy of prexigebersen combined with low-dose cytarabine compared with just low-dose cytarabine alo...

1,036

Earnings

-$0.27
-$0.19
-$0.10
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 19, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.